Why the Dual Mechanism Works Better: GIP activation enhances insulin secretion and may increase energy expenditure, amplifying semaglutide's effects Synergistic appetite suppression through dual pathway activation Improved glycemic control even in non-diabetic populations Advantages of Tirzepatide: Highest weight loss efficacy: 20-25% average reduction Superior cardiometabolic improvements Newer mechanism: ongoing research may unlock additional benefits Considerations: Shorter clinical history than semaglutide (approved for weight loss in 2023) Slightly higher GI side effect incidence in early trials Higher cost, available with transparent cash-pay pricing at Hartwater Wellness Which GLP-1 Medication Is Right for You
Weight Loss with GLP-1 Medicines Does Not Result in a Disproportionate Loss of Muscle Mass or Function in Obese Mice and Humans. Cell Reports
Xia J, Li Q, Liu Y, Ren Q, Gao J, Tian Y, Li J, Zhang B, Sun H, Liu S
( 10.1136/gut.2004.059741) [DOI] [PMC free article] [PubMed] [Google Scholar] 6.McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ
Figure 2: Photograph of Claude Bernard, unknown date
Emerging clinical evidence suggests that GLP-1-mediated insulin secretion regulation is impaired in conditions of obesity and insulin resistance [121]
